Clinical Case Reports (Jul 2022)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab

  • Naoto Saito,
  • Takeshi Hatanaka,
  • Sachi Nakano,
  • Yoichi Hazama,
  • Sachiko Yoshida,
  • Yoko Hachisu,
  • Yoshiki Tanaka,
  • Teruo Yoshinaga,
  • Kenji Kashiwabara,
  • Norio Kubo,
  • Yasuo Hosouchi,
  • Hiroki Tojima,
  • Satoru Kakizaki,
  • Toshio Uraoka

DOI
https://doi.org/10.1002/ccr3.6129
Journal volume & issue
Vol. 10, no. 7
pp. n/a – n/a

Abstract

Read online

Abstract An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients.

Keywords